Oncology

Latest News

Most of the patients who experienced superior outcomes with atezolizumab and chemotherapy had higher levels of NOTCH1 expression. | Image credit: Pixel-Shot - stock.adobe.com

NOTCH1 Levels Impact Immune Response in SCLC

By Jared Kaltwasser

September 2nd 2025

Patients with small cell lung cancer (SCLC) experienced better responses to immune checkpoint inhibitors if they had higher levels of NOTCH1 expression in a recent study.

The findings can help guide ongoing and future clinical trials to help solve remaining challenges in LS-SCLC. | Image credit: Jennifer - stock.adobe

Neoadjuvant Immunotherapy Plus Chemotherapy Shows Promise in LS-SCLC

By Jared Kaltwasser

August 31st 2025

PD-1 blockade has previously shown success in a first-line setting in ES-SCLC, and nab-paclitaxel is albumin-bound and solvent-free, which the investigators explained may minimize the toxicity associated with paclitaxel therapy. | Image credit: didesign - stock.adobe.com

Camrelizumab Plus Carboplatin, Nab-Paclitaxel Shows Efficacy in ES-SCLC

By Jared Kaltwasser

August 29th 2025

For rent sign | Image Credit: David Gales - stock.adobe.com

Housing Assistance May Help Renters With Cancer Better Withstand Medical Financial Strain

By Brooke McCormick

August 28th 2025

Patient with cancer undergoing chemotherapy | Image credit: RFBSIP – stock.adobe.com

Many Patients With Advanced Cancer Report Care Misaligned With Their Goals

By Hayden E. Klein

August 25th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

September 3rd 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

September 3rd 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

January 28th 2015

Screening Does Not Save Lives Except in Very Few Exceptions

Laura Joszt, MA

Screening for deadly illnesses does not necessarily save lives despite assumptions otherwise, according to a study published in the International Journal of Epidemiology.

Two Years In: The Impact of the ACA on Oncology

January 28th 2015

Two Years In: The Impact of the ACA on Oncology

Although the Affordable Care Act (ACA) was signed into law more than 4 years ago, many aspects of it are fairly new, which makes it difficult to analyze the impact the law has had on the United States healthcare system.

January 28th 2015

Pharma Expects Push-Back on Cancer Drug Costs

After Steven Miller, CMO at Express Scripts, announced last week that his company would like to influence the oncology market, Pharma seems to have paid heed.

January 28th 2015

Study Shows Targeted Biopsy Better Than Standard Biopsy, in Prostate Cancer

Targeted biopsy using new fusion technology that combines magnetic resonance imaging (MRI) with ultrasound is more effective than standard biopsy in detecting high-risk prostate cancer, according to a large-scale study.

Segment 2: Buyer Beware in the Diagnostic Test Market

January 27th 2015

Segment 2: Buyer Beware in the Diagnostic Test Market

There are currently 2 ways diagnostic tests can make it to market in the US: either through the FDA or laboratory-developed tests. This dual-pathway situation has led to a "buyer beware" market, according to Daniel F. Hayes, MD.

Panel Discussion: Defining Quality in Oncology: Is There a Common Ground?

January 27th 2015

Panel Discussion: Defining Quality in Oncology: Is There a Common Ground?

Although there have been some accusations of "cookbook medicine" with regards to measurement guidelines, panelists Dennis Scanlon, PhD, Jess DeMartino, PhD, Phyllis Torda, and Laura Long, MD, do see progress to remedy the situation and make guidelines more effective.

Payer Perspectives on the Role and Impact of QOPI Certification

January 27th 2015

Payer Perspectives on the Role and Impact of QOPI Certification

Although the healthcare industry values what it tends to measure, what is measured is not necessarily what should have the most value, according to John Fox, MD, senior medical director and associate vice president of medical affairs at Priority Health.

Panel Discussion: Perspectives on Economics and Outcomes of Community vs Hospital Oncology Practice

January 27th 2015

Panel Discussion: Perspectives on Economics and Outcomes of Community vs Hospital Oncology Practice

Education of both patients and providers will be necessary to temper expectations of cancer care treatment outcomes, according to panelists Ted Okon, BS, MBA, executive director of the Community Oncology Alliance, Debra Patt, MD, MPH, partner at Texas Oncology, and Stacie Dusetzina, PhD, assistant professor at the University of North Carolina, Chapel Hill.

Early Findings of the Oncology Patient-Centered Medical Home

January 27th 2015

Early Findings of the Oncology Patient-Centered Medical Home

One of the early findings from various oncology medical homes throughout the country was that they work, claimed Ted Okon, BS, MBA, executive director of the Coalition Oncology Alliance.

January 27th 2015

CUDC-101 Provides Encouraging Results in Phase 1 Head and Neck Cancer

The drug targets multiple proteins that are overexpressed in head and neck cancer, the study published in Clinical Cancer Research says.

January 26th 2015

Study Discovers Lack of Disease Awareness Among Women Diagnosed With Breast Cancer

The findings, published in the journal Cancer found that women diagnosed with breast cancer were not very aware of the disease characteristics such as tumor grade or stage. The researchers also found a bias based on the patient's race.

January 26th 2015

CAR T Cells and Bispecific Antibodies: A Double-Edged Sword?

Wile several big and small pharmaceutical companies have invested research efforts in developing these complex, and expensive, treatment regimens, early results from trials indicate safety issues.

January 25th 2015

ASCO Elects President for 2016-2017

Daniel F. Hayes, MD, FASCO, has been elected president of the American Society of Clinical Oncology.

January 24th 2015

Managed Care Minute: January 24, 2015

A one-minute look back at the week of January 19, 2015, in managed care, including Marilyn Tavenner's departure from CMS and oncology drug pricing.

January 23rd 2015

Bayer Wants Patient Engagement in Early Drug Development

Bayer is collaborating with MD Anderson in Texas to develop a questionnaire that will query a patient's disease-related symptoms, a step to include PROs in early drug development which could help reduce adverse effects in the final product.

Panel Discussion: Payer, Provider, and Patient Roles for Understanding the End-of-Life Care Equation: Cost vs Survival Time vs Quality of Life

January 23rd 2015

Panel Discussion: Payer, Provider, and Patient Roles for Understanding the End-of-Life Care Equation: Cost vs Survival Time vs Quality of Life

Amy Berman, BS, RN, Bruce Feinberg, DO, and Patti Forest, MD, MBA, sit on the first panel discussion at Patient-Centered Oncology Care 2015 and discuss advanced directives and end-of-life care.

Segment 7 - Final Thoughts About Which Patients, Which Drugs, and Which Treatment Timeline

January 23rd 2015

Segment 7 - Final Thoughts About Which Patients, Which Drugs, and Which Treatment Timeline

Segment 6 - Patient-Reported Outcomes and Other Important Measures

January 23rd 2015

Segment 6 - Patient-Reported Outcomes and Other Important Measures

Segment 5 - Surrogate End Points in Clinical Trials: The Right Information?

January 23rd 2015

Segment 5 - Surrogate End Points in Clinical Trials: The Right Information?

Segment 4 - Healthcare Policy: Its Impact on Innovation and Financial Waste

January 23rd 2015

Segment 4 - Healthcare Policy: Its Impact on Innovation and Financial Waste

Segment 3 - Justifying Costs: A Request for More Evidence

January 23rd 2015

Segment 3 - Justifying Costs: A Request for More Evidence

Segment 2 - Comparative Effectiveness Research and Innovation: Do They Clash?

January 23rd 2015

Segment 2 - Comparative Effectiveness Research and Innovation: Do They Clash?

Segment 1 - The Value of Innovation in Oncology Care

January 23rd 2015

Segment 1 - The Value of Innovation in Oncology Care

Making the Grade on Survivorship: How are Payers Performing?

January 23rd 2015

Making the Grade on Survivorship: How are Payers Performing?

As cancer care becomes more powerful and people survivor longer, cancer is becoming a chronic disease that patients need to learn how to live with and remain productive. Although the role of payers in survivorship isn't fully baked yet, there is more focus in the area, according to Ira Klein, MD, MBA, FACP, chief medical officer at Aetna.

When Is the Right Time for Palliative Care?

January 23rd 2015

When Is the Right Time for Palliative Care?

The Patient-Centered Oncology Care 2014 meeting started off with a talk by Marian Grant, DNP, RN, CRNP, of the University of Maryland School of Nursing, on the topic of palliative care. Although palliative care is appropriate for patients of all ages and in any stage of a serious illness and can be provided alongside curative or disease-modifying treatments, she says she often gets called in very late to offer palliative care to patients.

January 23rd 2015

Early Detection, Cutting Edge Treatments for Breast Cancer Patients

In 2 interviews with Physicians' Education Resource, LLC, award-winning journalist Joan Lunden and Patrick I. Borgen, MD, of Maimonides Medical Center in Brooklyn, NY, discuss breast cancer in advance of the 32nd Annual Miami Breast Cancer Conference.

January 23rd 2015

Vitiligo Could Be a Marker of Efficacy for Melanoma Drugs, Study Indicates

The retrospective analysis conducted in stage 3 and 4 immunotherapy-treated melanoma patients found that the development of vitiligo could serve as a clinical marker for effective antimelanoma immunity and improved clinical outcome.

January 23rd 2015

After Hep C, Express Scripts Aims to Influence Oncology Drug Costs

CMO Steven Miller has already started working with oncologists as the company plans the process of steering physicians to use preferred drugs.

January 22nd 2015

Telehealth Intervention Improved QoL Among Head and Neck Cancer Patients

A telehealth intervention experiment in head and neck cancer patients was found to relive some posttreatment distress symptoms.

January 22nd 2015

The Value of Ultrasound in Breast Cancer Detection

A study conducted in Connecticut showed that ultrasound identified an additional 3.2 women in a 1000 with breast cancer, following a negative mammogram. This has raised a debate on the utility of a screening ultrasound.

...

143 144 145 146 147 148 149 150 151

...

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions